These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31560372)

  • 21. Three-Year Outcomes of Oral Antibiotics vs Intravenous and Oral Antibiotics for Uncomplicated Acute Appendicitis: A Secondary Analysis of the APPAC II Randomized Clinical Trial.
    Selänne L; Haijanen J; Sippola S; Hurme S; Rautio T; Nordström P; Rantanen T; Pinta T; Ilves I; Mattila A; Rintala J; Marttila H; Meriläinen S; Laukkarinen J; Sävelä EL; Paajanen H; Grönroos J; Salminen P
    JAMA Surg; 2024 Jul; 159(7):727-735. PubMed ID: 38630471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.
    Sippola S; Haijanen J; Grönroos J; Rautio T; Nordström P; Rantanen T; Pinta T; Ilves I; Mattila A; Rintala J; Löyttyniemi E; Hurme S; Tammilehto V; Marttila H; Meriläinen S; Laukkarinen J; Sävelä EL; Savolainen H; Sippola T; Aarnio M; Paajanen H; Salminen P
    JAMA; 2021 Jan; 325(4):353-362. PubMed ID: 33427870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study.
    Ramirez J; Deck DH; Eckburg PB; Curran M; Das AF; Kirsch C; Manley A; Tzanis E; McGovern PC
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab135. PubMed ID: 34160474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
    Lodise T; Colman S; Stein DS; Fitts D; Goldberg L; Alexander E; Scoble PJ; Schranz J
    Open Forum Infect Dis; 2020 May; 7(5):ofaa145. PubMed ID: 32462049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
    Wang H; Charles CV
    Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
    Pai MP; Wilcox M; Chitra S; McGovern P
    Respir Med; 2021 Aug; 184():106442. PubMed ID: 34058682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
    Dillon C; Guarascio AJ; Covvey JR
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
    Covvey JR; Guarascio AJ
    J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Utility of Lefamulin: If Not Now, When?
    Mercuro NJ; Veve MP
    Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a
    Rodriguez GD; Warren N; Yashayev R; Chitra S; Amodio-Groton M; Wright K
    Front Med (Lausanne); 2023; 10():1225710. PubMed ID: 37575994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
    Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K
    Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia.
    Li Y; Zhu D; Peng Y; Tong Z; Ma Z; Xu J; Sun S; Tang H; Xiu Q; Liang Y; Wang X; Lv X; Dai Y; Zhu Y; Qu Y; Xu K; Huang Y; Wu S; Lai G; Li X; Han X; Yang Z; Sheng J; Liu Z; Li H; Chen Y; Zhu H; Zhang Y
    Curr Med Res Opin; 2021 Apr; 37(4):693-701. PubMed ID: 33534617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.